That's because the FDA is waiting for the completion of AZ's trial in the US. This should be definitely better run than the meta-trials done elsewhere and give clearer numbers.
A likely readout would be in March, or April.
The Oxford vaccine simply isn't that important to the US accordingly. We have Pfizer/BioNTech, Moderna, Johnson & Johnson, Novavax, along with Oxford. The US will end up with far more vaccine options than it needs. The EU is desperate for any vaccine supply because of how they massively screwed everything up. The US by contrast is going to be flooded with vaccine supply and is barely breaking a sweat. Given the US didn't even put forth its best effort and it's showing up the EU so dramatically, you know the EU really botched things.
Beg to differ there. We need to vaccinate the world. This is in the interests of the US. (Consider mutation etc). The analysis of the Oxford vaccine is that it is much easier to perform the logistics because of the significantly more modest refrigerations requirements. The US needs 7 billion to be vaccinated as much as anyone is my understanding.
$140 billion to vaccinate the world is not a large cost, and many nations will choose (have chosen) their own solutions, for the remaining, perhaps $60bn, that's not a large amount for developed nations to pay compared to the costs of reduced trade and potential further mutations, that's $60-$100 per person in developed countries in cash, or more likely however countries want to amortise that.